Download - Fabry disease
![Page 1: Fabry disease](https://reader033.vdocument.in/reader033/viewer/2022061609/556e40efd8b42a16278b4db7/html5/thumbnails/1.jpg)
FABRY DISEASERoshan Gunathilake MDJohn Hunter HospitalNewcastle, Australia
![Page 2: Fabry disease](https://reader033.vdocument.in/reader033/viewer/2022061609/556e40efd8b42a16278b4db7/html5/thumbnails/2.jpg)
Case report44 year-old-manR/weakness, gait ataxia and
nausea x 4 hoursRecurrent posterior circulation
ischemic stroke /TIAsRenal Transplant 2 yrs agoTreated HTN
![Page 3: Fabry disease](https://reader033.vdocument.in/reader033/viewer/2022061609/556e40efd8b42a16278b4db7/html5/thumbnails/3.jpg)
BackgroundCKD 2ry to FSGS 6 yrs agoHD x 4 yrsCadaveric renal transplant 2 yrs agoOn MMF, Tacrolimus & prednisoloneStable renal function, No Hx graft
rejectionNo Hx opportunistic infections /
malignancyHTN (irbesartan) x 8yrs, no other
vascular risk factors
![Page 4: Fabry disease](https://reader033.vdocument.in/reader033/viewer/2022061609/556e40efd8b42a16278b4db7/html5/thumbnails/4.jpg)
HistoryRecurrent transient vertigo 4
months ago, but no signs of brain stem dysfunction
Transient gait ataxia, andR/occipital infarction 3 months
agoNormal work up incl. metabolic
panel, Holter, TTE, Carotid duplex, MRA and thrombophilia screen
Started on clopidogrel + statin
![Page 5: Fabry disease](https://reader033.vdocument.in/reader033/viewer/2022061609/556e40efd8b42a16278b4db7/html5/thumbnails/5.jpg)
Sudden onset L/ hemiparesis, ataxia, dysarthria and nausea
No diplopia, facial weakness, vertigo, dysphagia or sensory loss
Symptoms started improving after 6-8 hrs, resolving after 24-48 hrs
![Page 6: Fabry disease](https://reader033.vdocument.in/reader033/viewer/2022061609/556e40efd8b42a16278b4db7/html5/thumbnails/6.jpg)
No cardiac HxNo Hx of acroparesthesiaNo family Hx of stroke,
premature vascular disease or kidney disease
No Hx of alcohol, tobacco or drug abuse
![Page 7: Fabry disease](https://reader033.vdocument.in/reader033/viewer/2022061609/556e40efd8b42a16278b4db7/html5/thumbnails/7.jpg)
Physical ExamResidual L/visual field defect,
otherwise normal CR N examL/ pronator drift, Grade 4
weaknessNo sensory deficitsNo cerebellar signsGait?
![Page 8: Fabry disease](https://reader033.vdocument.in/reader033/viewer/2022061609/556e40efd8b42a16278b4db7/html5/thumbnails/8.jpg)
Physical ExamNormal skin + corneaHR 84/min SRPeriph pulses+BP 138/84S1S2, no murmur/ carotid bruitLungs clearAbdo transplant kidney
![Page 9: Fabry disease](https://reader033.vdocument.in/reader033/viewer/2022061609/556e40efd8b42a16278b4db7/html5/thumbnails/9.jpg)
ImagingCT Brain: old
R/occipital strokeMRI brain : new
lesion of high intensity in the right pons on T2-weighted images
![Page 10: Fabry disease](https://reader033.vdocument.in/reader033/viewer/2022061609/556e40efd8b42a16278b4db7/html5/thumbnails/10.jpg)
Differential diagnosis of recurrent stroke/ TIAsCardioembolismPremature atherosclerotic disease ±
atheroembolismDissectionCerebral vasculitisInfectionAtrial Septal abnormalitiesSubstance abuseThrombophiliaRare: Fabry disease, MELAS, CADASIL
![Page 11: Fabry disease](https://reader033.vdocument.in/reader033/viewer/2022061609/556e40efd8b42a16278b4db7/html5/thumbnails/11.jpg)
InvestigationsESR 13Hb 145 WBC 5.4PLT 235Cr 112LFTs normalLipid profile
normalFBSL 4.9CXR - NAD
Vasculitic screen –ve
Syphilis serology –ve
S.homocysteine normal
CSF exam – normal protein, glucose, cells & microscopy; no oligoclonal bands
-ve VZV PCR
![Page 12: Fabry disease](https://reader033.vdocument.in/reader033/viewer/2022061609/556e40efd8b42a16278b4db7/html5/thumbnails/12.jpg)
Cardiac InvestigationsECG - SR, LVH24 h telemetry -
NADTTE – LVH,
“binary apperance”
TOE – No septal defect/ PFO, No intracardiac source of thrombi
![Page 13: Fabry disease](https://reader033.vdocument.in/reader033/viewer/2022061609/556e40efd8b42a16278b4db7/html5/thumbnails/13.jpg)
InvestigationsPlasma α-galactosidase A activity
very low (on 2 occasions)Pedigree analysis : no other
affected family members
![Page 14: Fabry disease](https://reader033.vdocument.in/reader033/viewer/2022061609/556e40efd8b42a16278b4db7/html5/thumbnails/14.jpg)
Referred to Statewide Fabry disease service for consideration for counseling, genetic testing and ?ERT
![Page 15: Fabry disease](https://reader033.vdocument.in/reader033/viewer/2022061609/556e40efd8b42a16278b4db7/html5/thumbnails/15.jpg)
Fabry DiseaseX-linked inborn error of
metabolismDeficient -Galactosidase A
enzyme activityProgressive
globotriaosylceramide (GL-3) accumulation
![Page 16: Fabry disease](https://reader033.vdocument.in/reader033/viewer/2022061609/556e40efd8b42a16278b4db7/html5/thumbnails/16.jpg)
Severe endothelialGL-3 accumulation
![Page 17: Fabry disease](https://reader033.vdocument.in/reader033/viewer/2022061609/556e40efd8b42a16278b4db7/html5/thumbnails/17.jpg)
The classical phenotype
Early (adolescence)◦Acroparesthesia, ◦Angiokeratomas, anhydrosis◦Corneal opacities
Late (4th- 5th decade)◦Renal failure◦Recurrent stroke◦Cardiomyopathy
![Page 18: Fabry disease](https://reader033.vdocument.in/reader033/viewer/2022061609/556e40efd8b42a16278b4db7/html5/thumbnails/18.jpg)
Fabry Disease Progression
0
Acroparesthesia
Renal Disease
CNS Disease
Cardiac Disease
[Age] 40+
Diagnosis (average)
![Page 19: Fabry disease](https://reader033.vdocument.in/reader033/viewer/2022061609/556e40efd8b42a16278b4db7/html5/thumbnails/19.jpg)
![Page 20: Fabry disease](https://reader033.vdocument.in/reader033/viewer/2022061609/556e40efd8b42a16278b4db7/html5/thumbnails/20.jpg)
![Page 21: Fabry disease](https://reader033.vdocument.in/reader033/viewer/2022061609/556e40efd8b42a16278b4db7/html5/thumbnails/21.jpg)
The later-onset phenotype
Residual α-galactosidase A activity due to missense and splicing mutations
Lack the early manifestations Typically present with cardiac,
renal or cerebrovascular manifestations
![Page 22: Fabry disease](https://reader033.vdocument.in/reader033/viewer/2022061609/556e40efd8b42a16278b4db7/html5/thumbnails/22.jpg)
Diagnosis of Fabry Disease
Presumptive diagnosis – observation of symptoms and laboratory
findings– family history/medical pedigree
Definitive diagnosis – enzyme assay in plasma, leukocytes, or
biopsied tissue– gene mutation analysis or linkage
analysis
![Page 23: Fabry disease](https://reader033.vdocument.in/reader033/viewer/2022061609/556e40efd8b42a16278b4db7/html5/thumbnails/23.jpg)
Fabrazyme® Shown in randomized, double-blind,
placebo-controlled trials to be safe and effective at 1 mg/kg every 2 weeks
Clear the vascular endothelial glycolipid deposits and reverse, stabilize or markedly improve symptoms
Early intervention is essential to avoid the irreversible renal, cardiac and cerebro-vascular complications
Cost USD 200,000/ patient per annum